Phio Pharmaceuticals Corp.
Developing RNAi-based immuno-oncology therapeutics for melanoma and other skin cancers.
PHIO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US74979C5013 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 411 SWEDELAND ROAD, 19406 KING OF PRUSSIA
- Website:
- https://phiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation immuno-oncology therapeutics. Co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNA interference (RNAi), the company leverages its proprietary INTASYL® technology platform. This platform uses self-delivering small interfering RNA (siRNA) to silence specific genes that inhibit the immune system's ability to attack tumors, thereby making immune cells more effective at killing cancer cells. The company's clinical pipeline is concentrated on developing treatments for cutaneous squamous cell carcinoma (cSCC) and melanoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Phio Pharmaceuticals Corp. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Phio Pharmaceuticals Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Phio Pharmaceuticals Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
